SLC1A2 and neurodegenerative disease: We believe that the availability of the cryo-EM structures ofEAAT2 will offer the opportunity to initiate a structural-based drugdesign campaign to facilitate the development and screening of high-affinityPAMs able to modulate EAAT2 activity while using them as imaging toolsto detect change in EAAT2 density in neurodegenerative diseases.